N.I.S of AIT in Adult Patients With House Dust Mite Allergy in Real Practice in France

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1508 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-05-09

Study Completion Date

2020-09-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Non-interventional study to investigate the safety and tolerability of allergy immunotherapy ACARIZAX® 12 SQ-HDM in real-life clinical practice in adults patients (\>18 years) with house dust mite allergy over a period of 12 months.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Potency of HDM Sublingual AIT Tablets in Assuring the Persistency of Asthma Control in HDM Allergic Patients With Severe Asthma, Treated With Tezepelumab

NCT07013123

Severe Asthma Allergy to House Dust Mites

NOT_YET_RECRUITING PHASE3

A One Year Trial Evaluating the Safety and Efficacy of the ALK House Dust Mite Allergy Tablet

NCT01454544

House Dust Mite Allergy

COMPLETED PHASE3

Evaluate Measurement Instruments Relevance in Assessing Effectiveness of ACARIZAX® in House Dust Mite Allergic Rhinitis

NCT06151938

Allergic Rhinitis Due to House Dust Mite Allergic Asthma

ENROLLING_BY_INVITATION

House Dust Mite Injection Immunotherapy in Elderly Patients.

NCT03209245

Allergen Immunotherapy in Elderly Patients

COMPLETED PHASE3

Vestibular Versus Sublingual Route of AIT Tablets

NCT05119751

Hypersensitivity

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Condition:

* persistent moderate to severe HDM allergic rhinitis despite use of symptom-relieving medication
* HDM allergic asthma not well controlled by inhaled corticosteroids and associated with mild to severe HDM allergic rhinitis. Patients' asthma status should be carefully evaluated before the initiation of treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Allergic Rhinitis Due to House Dust Mite Allergic Asthma Due to Dermatophagoides Farinae Allergic Asthma Due to Dermatophagoides Pteronyssinus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tablet, Dispersible

1 tablet/day with 12 SQ-HDM per lyo-tablet

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ACARIZAX 12 SQ-HDM Standardised allergen extract from house dust mite

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* At the discretion of the investigator, patient who will be prescribed ACARIZAX® in line with the approved Summary of Product Characteristics (SmPC) and who have been informed, after explicit written explanation and willing to participate in the study by signed consent